Dabrafenib-Trametinib Combination Approved for Mutation-Positive Thyroid Cancer

Share this content:
FDA approval was based on results from a phase 2 clinical study assessing the efficacy of the combination treatment among patients with advanced or metastatic rare cancers.
FDA approval was based on results from a phase 2 clinical study assessing the efficacy of the combination treatment among patients with advanced or metastatic rare cancers.

The US Food and Drug Administration (FDA) approved dabrafenib and trametinib combination therapy for the treatment of patients with unresectable and metastatic BRAF V600E mutation-positive anaplastic thyroid cancer (ATC), according to a FDA news release.

The combination is the first FDA-approved treatment for ATC; the dabrafenib and trametinib combination had been previously approved for BRAF V600 mutation positive metastatic melanoma and non-small cell lung cancer.

The FDA based its approval on results from an open-label, phase 2 clinical study assessing the efficacy of the combination treatment among patients with advanced or metastatic rare cancers who had no standard-of-care options available. Study participants received dabrafenib 150 mg twice daily and trametinib 2 mg once daily until unacceptable toxicity, disease progression, or death.

Of 23 evaluable patients, 4% and 57% achieved a complete or partial response, respectively. Of the 14 patients who had a response, 64% (9 patients) did not have significant tumor growth for 6 months or longer.

The side effect profile of dabrafenib and trametinib in combination was consistent with those previously reported. Commonly reported adverse effects include fever, rash, arthralgia, myalgia, nausea, vomiting, diarrhea, decreased appetite, dyspnea, and hypertension.

Reference

FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer [news release]. Silver Spring, MD: US Food and Drug Administration; Updated May 4, 2017.https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm606686.htm?utm_campaign=05042018_PR_FDA%20approves%20new%20uses%20for%202%20drugs%20for%20BRAF%20positive%20patients&utm_medium=email&utm_source=Eloqua. Accessed May 7, 2018.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs